Cargando…

New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives

[Image: see text] Prostate cancer is among the leading causes of cancer related death of men in the United States. The ERG gene fusion leading to overexpression of near full-length ERG transcript and protein represents most prevalent (50–65%) prostate cancer driver gene alterations. The ERG oncoprot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eldhose, Binil, Pandrala, Mallesh, Xavier, Charles, Mohamed, Ahmed A., Srivastava, Shiv, Sunkara, Anu D., Dobi, Albert, Malhotra, Sanjay V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591719/ https://www.ncbi.nlm.nih.gov/pubmed/34790292 http://dx.doi.org/10.1021/acsmedchemlett.1c00308

Ejemplares similares

Oncogenic activation of ERG: A predominant mechanism in prostate cancer
por: Sreenath, Taduru L, et al.
Publicado: (2011)

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors
por: Dubovenko, Alexey, et al.
Publicado: (2015)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
por: Bowling, Gartrell C., et al.
Publicado: (2023)

ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men
por: Baohong, Jiang, et al.
Publicado: (2019)

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer
por: Xiao, Qingyu, et al.
Publicado: (2018)

INSPIRE-HEP Ergys Dona Summer Student Report 2015
por: Dona, Ergys
Publicado: (2015)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1
por: Kumar, Parameet, et al.
Publicado: (2016)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety
por: Pandrala, Mallesh, et al.
Publicado: (2022)

Observationes et Epicrisis de Corticis Peruviani salutari et proficuo usu in Podagra
Publicado: (1805)

Cytotoxic Activity of BornUSU I towards T47D Breast Cancer Cells
por: Nasution, Nadiya Anandita, et al.
Publicado: (2019)

Novel CMKLR1 Inhibitors for Application in Demyelinating Disease
por: Kumar, Vineet, et al.
Publicado: (2019)

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag
por: Rastogi, Anshu, et al.
Publicado: (2016)

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods
por: He, Jintang, et al.
Publicado: (2015)

Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody
por: Mohamed, Ahmed A., et al.
Publicado: (2010)

PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

Plumbagin reduces human colon cancer cell survival by inducing cell cycle arrest and mitochondria-mediated apoptosis
por: ELDHOSE, BINIL, et al.
Publicado: (2014)

A New Nrf2 Inhibitor Enhances Chemotherapeutic Effects in Glioblastoma Cells Carrying p53 Mutations
por: Afjei, Rayhaneh, et al.
Publicado: (2022)

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India
por: Rawal, Sudhir, et al.
Publicado: (2013)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

De Nervi Sympathetici Humani Fabrica, usu, et morbis, Commentio Anatomico-physiologico-pathologica, Tabulis Aeneis et Lithographicis Illustrata
Publicado: (1830)

ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer
por: Kacprzyk, Lukasz A., et al.
Publicado: (2013)

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence
por: Yan, Wusheng, et al.
Publicado: (2019)

Muon radiography and deformation analysis of the lava dome formed by the 1944 eruption of Usu, Hokkaido —Contact between high-energy physics and volcano physics—
por: TANAKA, Hiroyuki K. M., et al.
Publicado: (2008)

Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer
por: Lorenzin, Francesca, et al.
Publicado: (2022)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients
por: Abdel-Hady, Ahmed, et al.
Publicado: (2017)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
por: Bhalla, Ritu, et al.
Publicado: (2013)

Expression and ERG regulation of PIM kinases in prostate cancer
por: Eerola, Sini K., et al.
Publicado: (2021)

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men
por: Duncan, Allison, et al.
Publicado: (2023)

Prostate cancer marker panel with single cell sensitivity in urine
por: Nickens, Kristen P., et al.
Publicado: (2015)

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
por: Burdelski, Christoph, et al.
Publicado: (2015)

ERG Immunohistochemistry and Clinicopathologic Characteristics in Korean Prostate Adenocarcinoma Patients
por: Suh, Ja Hee, et al.
Publicado: (2012)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gc0d9ff34sh0cl1uquegtiga7e